New treatment option shows promise for severe hypertrophic cardiomyopathy in children
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to ...
Jan 8, 2025
0
0